Source comparison
ARA-290 vs BPC-157
BPC-157, a 15-amino acid peptide derived from human gastric juice, has robust preclinical evidence for musculoskeletal repair, particularly tendons and ligaments. It also shows neuroprotective properties in some models. Factor ARA-290 BPC-157 Primary focus Ner
This comparison does not assign a generated winner or score.
- BPC-157, a 15-amino acid peptide derived from human gastric juice, has robust preclinical evidence for musculoskeletal repair, particularly tendons and ligaments. It also shows neuroprotective properties in some models.
- Factor
- ARA-290
- BPC-157
- Primary focus
- Nerve protection, systemic inflammation
- Tendon/ligament repair, gut healing
- Clinical trials
- Multiple Phase 2 completed
- Limited human data
- Mechanism
- Innate repair receptor activation
- Multiple pathways including VEGF, growth hormone
- Best for
- Neuropathy, nerve damage
- Soft tissue injuries, gut issues
- Administration
- Subcutaneous
- Subcutaneous or oral
- Research maturity
- More human data
- More preclinical data
- BPC-157's mechanisms differ from ARA-290. It works partly through nitric oxide pathways and directly influences growth factor expression.
- For localized musculoskeletal injuries, BPC-157's effects may be more targeted. For systemic nerve conditions and inflammation, ARA-290's mechanism may prove more relevant.
- Some researchers combine both, hypothesizing that BPC-157's local tissue effects complement ARA-290's systemic nerve and inflammation support. However, combination protocols lack systematic study.